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INTRODUCTION 
Preference-based measures of health (PBMH) have been developed primarily for use 
in economic evaluation. They have two components, a standardized, multidimensional 
system for classifying health states and a set of preference weights or scores (1) that 
generate a single index score for each health state  defined by the classification, where 
full health is one and zero is equivalent to death.  A health state can have a score of 
less than zero if regarded as worse than being dead.  These PMBH can be 
distinguished from non-preference-based measures by the way the scoring algorithms 
have been developed, in that they are estimated from the values people place on 
different aspects of health rather than a simple summative scoring procedure or 
weights obtained from techniques based on item response patterns (e.g., factor 
analysis or Rasch analysis).   
 
The use of PBMH has grown considerably over the last decade with the increasing 
use of economic evaluation to inform health policy, for example through the 
establishment of bodies such as the National Institute for Clinical Excellence in 
England and Wales (2) and the Health Technology Board in Scotland (3) and similar 
agencies in Australia (4) and Canada (5).  Preference-based measures have become a 
common means of generating health state values for calculating quality-adjusted life 
years (QALY).   The status of PBMH was considerably enhanced by the 
recommendations of the U.S. Public Health Service Panel on Cost-Effectiveness in 
Health and Medicine to use them in economic evaluation (6).  A key requirement for 
PBHM in economic evaluation is that they allow comparison across programs.  
 
While PBMH have been developed primarily for use in economic evaluation, they 
have also been used to measure health in populations.  PBHM provide a better means 
than a profile measure of determining whether  there has been an overall improvement 
in self-perceived health.  The preference-based nature of their scoring algorithms also 
offers an advantage over non-preference-based measures since the overall summary 
score reflects what is important to the general population. A non-preference-based 
measure does not provide an indication to policy makers of the overall importance of 
health differences  between groups or of changes over time.   
 
The purpose of this paper is to critically review methods of designing preference-
based measures.  The paper begins by reviewing approaches to deriving preference 
weights for PBMH, and this is followed by a brief description and comparison of five 
common PBMH. The main part of the paper then critically reviews the core 
components of these measures, namely the classifications for describing health states,  
the source of their values, and the methods for estimating the scoring algorithm. The 
final section proposes future research priorities for this field.   
 
APPROACHES TO OBTAINING PREFERENCE WEIGHTS FOR 
MEASURES OF HEALTH 
 
There are three empirical approaches to deriving preference weights for measures of 
health:  i) empirical mapping onto an existing PBMH, ii) mapping onto a respondent’s  
own health valuation, and iii) asking respondents to value states defined by the health 
measure.  While existing preference-based measures are currently based on the third 
approach, it is important to understand the potential role of the alternatives.  
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Mapping between measures 
The approach of empirically mapping a health measure onto a PBMH so as to obtain  
preference weights for the former has been used in numerous studies. This approach 
requires the PBMH and the non-preference-based measure to be administered to the 
same population.  The approach was used by Fryback et al. (7) in the Beaver Dam 
study and Nichol et al. (8), both of whom mapped the generic SF-36 onto  preference-
based measures.  Tsuchiya et al (9) and Brazier et al (10) have mapped PBHMs onto 
condition-specific measures.  These studies have regressed the dimension scores of 
the non-preference-based measure onto the preference-based measure.    
 
This approach can be pragmatically useful, but it makes several assumptions.  First, it 
assumes that the items used to score the dimensions have equal importance, and 
second, that the intervals between the response choices are equally important to 
people.  These assumptions can be relaxed by modelling each item response as a 
dummy variable (9). A more important limitation is the assumption that the 
preference-based measure covers all the important aspects of health covered by the 
non-preference-based measure. If it does not, important dimensions of health might 
not be valued appropriately.  Mapping onto an existing PBMH should be viewed as a 
second best compared to the direct valuation of the health measure. 
 
Valuing a health measure using direct values for health states 
This approach involves administering the health measure alongside a valuation 
question about the respondent’s own health.  Such an approach was taken by 
Lundberg and colleagues (11) and involved administering the SF-12 health status 
questionnaire alongside a self-administered version of the time-trade-off (TTO) 
technique in a postal survey of 8,000 members of the general population. The TTO 
question asks respondents to consider the number of years of life they would be 
willing to sacrifice in order to live the remainder of their life in full health.  SF-12 
item responses (among other variables such as age) were regressed against their TTO 
value to provide a set of preference weights for the SF-12.    
 
This study was limited because the health states were those of a random sample of the 
general population.  The sample of states valued in the survey was therefore not 
determined by any statistical design but by their natural occurrence in the population.  
As many severe states are quite rare, this reduces the ability of the model to predict  
values for more severe states. These limitations could be partly overcome by careful 
sampling of people with a wide range of conditions, but there will always be people in 
some medical conditions that could not participate in such a survey, necessitating the 
use of proxies.     
 
In conclusion, this approach captures only the values of those people in the states.  
This may be seen as a problem for those seeking to implement the Washington 
Panel’s recommendations to use ‘societal values’.  The issue of whose values is 
examined latter in this paper. 
 
Hypothetical valuation of health states    
The approach adopted by PBMH developers to date involves asking respondents 
(typically adult members of the general population) to imagine being in a health state. 
They could be asked to imagine the state on someone else’s behalf, perhaps as a proxy 
or by taking a third-party perspective (such as behind a ‘veil of ignorance’), but most 
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applications ask respondents to imagine they are in the state.  This has a logistical  
advantage over the previous direct approach because it allows a single respondent to 
value numerous states and the researcher can select the states being valued according 
to a proper statistical design. This approach conforms most closely to the 
recommendations of the Washington Panel.   
 
EXISTING PREFERENCE-BASED MEASURES OF HEALTH 
 
The five preference-based measures considered in this section are the Quality of Well-
Being (QWB) scale (12), the Health Utility Index (HUI) versions two and three (HUI-
2 and HUI-3) (13,14), EQ-5D (15,16), and the SF-6D - a derivative of the SF-36 and 
SF-12 (17,18). These instruments were chosen because they are the most widely used.  
In Table I, which summarizes their characteristics, we see that existing preference-
based measures differ in the content of their descriptive systems, the valuation 
technique, and the method of extrapolation.  And yet their descriptive systems share a 
common structure, as they all have multilevel dimensions.  Furthermore, despite 
differences in methods of valuation, all preference data were obtained from a sample 
of the general population (although the HUI-2 was valued by a random sample of 
parents from Hamilton, Ontario).     
 
All five instruments purport to be generic.  Even so, they differ in defining health and 
in the dimensions they cover.   The developers of the HUI instruments restrict health 
to ‘beneath the skin’ and exclude those consequences for quality of life (QOL) 
affecting the person’s functioning in society, such as role and social functioning. By 
contrast, the QWB, SF-6D, and EQ-5D include ‘out-of-skin’ aspects of health. The 
HUI-2 was designed for children and the rest for adults. The instruments also differ 
greatly in size, with between five and eight dimensions and two to six levels on each 
dimension, resulting in the number of potential health states ranging from 243 for the 
EQ-5D to 972,000 for the HUI-3.   
 
The instruments use different valuation techniques to elicit preferences, including the 
visual analogue scale (VAS), standard gamble (SG), and TTO (see definitions in next 
section).  The HUI-2 and HUI-3 health states were not directly valued using SG but 
rather via a transformation of VAS values.  The five measures were also valued using 
different variants of the valuation techniques.   Finally, all five measures have too 
many states to be valued in one survey (with the possible exception of EQ-5D), and 
thus values must be extrapolated from a sample of states defined by their respective 
classifications. This was done for three of the measures by statistical modelling (EQ-
5D, QWB, and SF-6D), and the HUI-2 and -3 use multi-attribute utility theory 
(MAUT). Valuation work has been replicated across a number of countries for the 
EQ-5D, SF-6D and HUI-2&3. 
 
Comparison of measures 
This section briefly compares the five PBMH in terms of practicality, reliability, and 
degree of agreement.   
 
There is little to choose between the instruments on the basis of practicality, with each 
now having self-completed versions.   The EQ-5D has just five questions, but it is  
closely followed by the 15 items for the HUIs and 36 (or just the 11 used to construct 
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the classification) for the SF-6D.  Stability over time in those whose health has not 
changed has been demonstrated for most instruments, and there is no reason to 
suppose them to be worse than non-preference-based measures (19).   The standard 
deviations of the preference scores, however, are larger for the EQ-5D and HUI-3 
than the SF-6D (20-22), because the EQ-5D and HUI-3 cover a larger range of states.   
 
Content validity depends on the aspects of health the user wishes to cover and also on 
the disease group and age of the patients. There are also issues about perspective and 
whether social health is relevant.  It is also evident from the descriptions that the SF-
6D may suffer from ‘floor effects’ on dimensions of physical functioning and role 
limitation, where many respondents choose the lowest response category, and this has 
been borne out in recent empirical comparisons (20-22).  Conversely, concern has 
been expressed that the EQ-5D suffers from a ceiling effect because large numbers of 
patients are given states of full health (23). 
 
Among those who use a choice-based valuation technique, the HUI-2 and -3 and SF-
6D might be preferred to the EQ-5D by those who regard the SG as the ‘gold 
standard’ and EQ-5D by those who prefer TTO.  The SG utilities for the HUIs have 
been derived from VAS values using a power transformation that has been criticized  
(see above). The valuation of the HUI has also been obtained from a smaller and less 
representative sample of the general population than the valuation survey of the EQ-
5D in the UK and US. A further difference between them is the methods of modelling 
the values for health states, with the HUIs using MAUT and the rest using statistical 
inference. The review in the next section concludes there is little evidence on their 
relative predictive performance. 
 
The measures seem to be moderately correlated at around 0.5 to 0.6, and the 
differences in mean values for patient groups are often just 0.05 on the zero-to-one  
utility scale, but this makes for significant systematic variation between instruments 
(20,21).  Comparisons of the SF-6D with the EQ-5D and HUI-3 have shown the 
former to generate higher values for more severe states and lower values for the 
mildest states.  Furthermore, these cross-sectional differences were found to translate 
into significant differences in the size of change measured over time in one patient 
group (20).   The variation is a product of the differences between the instruments, but 
it is not possible to determine whether this variation is driven by differences in their 
descriptive systems, techniques of valuation, or methods of extrapolation.   
 
The next section critically reviews the three components of PBMH:  the descriptive 
systems, valuation techniques, and methods of extrapolation. 
 
REVIEW OF METHODS 
 
Descriptive systems 
Two important issues in designing a descriptive system for a generic preference-based 
measure are (i) the definition of health and (ii) the construction of descriptive systems 
for PBMH.    
 
Definition of health 
The developers of the HUI advocate a ‘beneath the skin’ definition of health that  
excludes social activities and work (e.g., social and role dimensions on the SF-6D and 
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usual activities in the EQ-5D). Social and role activities are deemed the result of the 
personal preferences of the respondent as well as his/her state of health and it has 
been argued should be excluded from the descriptive system.  For the HUI measures, 
this also helps to achieve orthogonality or independence between attributes in the 
classification of health state, which is important for the application of MAUT and, to 
a lesser extent, the statistical approaches.   
 
There is a long history of having ‘out of skin’ consequences in measures of health, 
due in part to the original WHO (World Health Organization) definition that included 
social health (24).  It could also be argued that the impact on role and social activities 
is important in helping respondents in a valuation survey to fully understand the 
impact of a health state on their QOL.  It effectively reduces the imaginative workload 
being demanded of respondents.  
 
This debate has interesting parallels in the QOL literature in general through the 
notion of ‘response shift’ (25), where the impact of a health state on a person’s QOL 
is not stable.  A sudden change in health may initially have a substantial impact, but 
gradually people learn to cope and adapt to their limitations in a number of ways, and 
over time the impact lessens. Those measures having role and social dimensions are 
likely to be even more prone to this ‘response shift’. Whether adaptation should be 
excluded from the final values given to states is a normative question addressed in a 
later section. 
 
 
Most preference-based measures of health have a generic descriptive system 
(14,17,26).    These have been found, however, to be inappropriate or insensitive for 
many medical conditions (e.g., 27-29).   Condition-specific descriptions may be more 
sensitive to changes in the condition than generic measures and more relevant to the 
concerns of patients (30).  There is a concern, however, that condition-specific PBMH 
fail to achieve comparability.  Differences in scores between measures (whether 
generic or condition specific) result from differences in the methods of valuation as 
well as the descriptive system.  In principle, if the descriptive system is valued on the 
same full health–dead scale using the same variant of the same valuation technique 
employing a comparable population sample, the valuations should be comparable.  
Any remaining differences in values should be a legitimate consequence of the 
descriptive system.  This, however, assumes that the value of a dimension is 
independent of those dimensions outside of the descriptive system, and this requires 
empirical testing.   
 
Construction and validation of descriptive systems for PMBH  
Although there are difficulties in establishing the validity of the values generated by a 
preference-based measure (as discussed below), it is important to show that a 
descriptive system accurately describes the health state. Little has been written in the 
economics literature about this aspect of validity (31).  Published economic 
evaluations rarely address the issue even though small  differences in descriptions of 
health states can substantially alter the results. There has been some criticism 
expressed of specific generic preference-based measures but little systematic 
evaluation of their descriptive systems. The assessment of the validity of the 
descriptive system of a preference-based measure should be undertaken with the same 
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rigor as would be applied to non-preference-based measures. There are some 
important differences of principle, however, and these are explained below.    
 
Content and face validity 
The psychometric criteria of content and face validity, although subjective, are 
important in assessing the comprehensiveness, relevance, and sensitivity of the 
dimensions of preference-based measures.  Content, in terms of dimensions and items,  
limits the attributes being covered by the measure.   Economists, who are concerned 
with ensuring that the measure correctly reflects a person’s utility function, will prefer 
an approach which generates items and dimensions from patients. This has been 
pursued to a limited extent in the development of some existing instruments, but most 
preference-based measures were constructed primarily by teams of experts.    
 
Item Response theory 
IRT provides a powerful technique for understanding the relationship between items.  
It is based on the assumption that item responses are determined by their degree of 
difficulty along some spectrum of a unidimensional construct.  This has been very 
helpful in understanding the relationship between items and has been used, among 
other purposes, to assist in selecting items for an instrument and in scoring the items.  
Recent years have seen a rapid expansion of the application of IRT to the construction 
and testing of non-preference-based measures.   
 
IRT has potential in helping to construct the descriptive systems of preference-based 
measures.  It was used in the selection of items for the physical functioning dimension 
of the SF-6D from the 10 items of this dimension in SF-36 (17).  By pooling items 
from different PBMH and non-preference-based measures, IRT can assist in 
understanding the severity range covered by the descriptive systems of the preference-
based measures.  IRT may identify significant gaps in the descriptive classifications 
and provide candidate items for improving them.    
 
It is important to understand the limitations of the IRT, however.   It would make no 
sense to apply IRT across dimensions for a preference-based measure, anymore than 
it would for a non-preference-based measure.  Furthermore, while the advocates of 
IRT claim it generates an interval scale and this might be true for the health concept 
being measured, it does not provide a measure of strength of preference with the 
required interval properties.  
 
Construct validity 
Having an empirically based means of testing the descriptive validity of an instrument 
is important.  Construct validation is appropriate for testing the validity of the 
description of health or health change underlying a PBMH.  The ability of an 
instrument to reflect known or expected differences in health is an essential precursor 
to its ability to reflect preferences.  Such tests should be undertaken on the unscored 
descriptions of an instrument, however.    Otherwise, there is a danger that the failure 
of a score to detect a difference found by a condition-specific QOL measure is 
incorrectly interpreted to imply that the descriptive component of the preference-
based instrument is insensitive. The score of a preference-based measure may fail to 
detect the difference simply because this difference is not valued by patients.   
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Valuation  
The methods of valuation underpin preference-based measures and have been a topic 
of considerable debate in the health economics literature.  The key areas of concern 
have been the choice of technique, the variant of the technique, the problem of states 
worse than death, and the appropriate sources of values.  
 
Valuation Technique 
The five preference-based measures reviewed in this paper have used VAS, SG, or  
TTO, and much has been written on the relative virtues and flaws in each of these 
techniques.  This section attempts to summarize this well-trodden path.   
 
Several informative reviews have compared the VAS, SG, and TTO techniques in 
terms of practicality, reliability, and validity (32-36).  Generally, all three techniques 
have been reported to be practical and acceptable for most populations, but VAS is 
considered marginally better in terms of response rate, cost, and consistency of 
responses (33)..  On the other hand, the validity of VAS as a measure of the strength 
of preference has been challenged (37-39). The main criticism is that a rating scale 
does not confront the respondent with the notion of opportunity cost and so does not 
reflect the economist’s notion of strength of preference. Interviews with respondents 
indicate that they did not intend it to reflect their preferences (37,39,40).   When asked, 
respondents talk about concepts of fitness or the natural history of illness and not the 
value of health.    
SG and TTO present respondents with a choice and offer a more theoretically 
appealing measure of strength of preference (i.e., involving opportunity cost). SG asks 
respondents to make a choice between alternative outcomes where one of them 
involves uncertainty. Respondents are asked how much risk in terms of probability of 
death or some other bad outcome they are willing to accept to avoid living in the 
certainty of the health state being valued.  This technique is based on the Expected 
Utility Theory of decision making under uncertainty developed by Von Neumann and 
Morgenstern (41), which rests on a set of axioms about the nature of individual 
preferences when prospects are uncertain.  The TTO technique, developed as  an 
alternative to SG (32), was designed to overcome the problems of explaining 
probabilities to respondents. The TTO technique asks the respondent to choose 
between two alternatives with certain prospects, i.e., shorter years (x) in full health 
and longer years (t) in the health state being valued.  Respondents are asked to 
consider trading a reduction in their length of life (t-x) for an improvement in health.  
The health state valuation is the fraction of healthy years equivalent to a year in a 
given health state, i.e., x/t. 
 
SG has the most rigorous foundation in theory in the form of the Expected Utility 
Theory of decision making under uncertainty.  There are theoretical arguments against 
SG in valuing health states, however (34), and little empirical support for Expected 
Utility Theory (42,43).  There are also concerns about the empirical basis of the TTO 
technique.   Some evidence suggests that the time spent in a health state and the time 
at which it occurs affect TTO values (44,45). A key review by Bleichrodt (46) 
summarized the different sources of bias in each of these techniques and concluded 
that SG is subject to mainly upward bias, whereas TTO is subject to upward and 
downward bias, and so he concludes that, overall, TTO may be preferred.  There is 
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currently no consensus regarding the best technique. One solution might be to try to 
correct for these biases (47).   
 
A further consideration is that the SG ‘utilities’ of the HUI-2 and HUI-3 are derived 
from VAS valuations on the basis of an estimated power function where the 
difference between VAS ratings and SG utilities is assumed to be a person’s attitude 
toward risk.  This conclusion was based on the suggestion of Dyer and Sarin (48), but 
the validity of the power transformation has been questioned in the literature. Dolan 
and Sutton (49) and Stevens et al (50)  have all demonstrated that other specifications 
fit the data as well as and in some cases better than a power function.  
 
More recently, there has been interest in basing valuations on ordinal data from 
ranking and discrete choice experiments.   The use of ordinal individual data to 
generate cardinal health state values draws on random utility theory.  It may prove to 
be a promising alternative to SG and TTO, particularly in more vulnerable 
populations, because empirical work has found that it can produces similar values for 
the EQ-5D, SF-6D, and HUI-2 (51,52). 
 
Variant of the technique 
Differences in variant may prove more important than choice of technique.  It has 
been shown in numerous studies that SG responses are subject to framing effects, 
such as whether the probabilities are expressed in terms of success or failure.  SG has 
been found to generate inconsistent valuations with changes to the lower anchor   
(53).   
 
There are a wide range of variants, including (i) mode of administration (interview or 
self-completion, computer or paper administration), (ii) the use of props, (iii) 
presentation of probabilities, (iv) time allowed for reflection,  and (v) individual 
versus group interviews.  Few publications in the health economics literature have 
compared these alternatives, although several researchers have undertaken 
considerable efforts to try to improve the quality of the data from SG and TTO (e.g., 
35,54).  The evidence is that values for health states vary considerably between 
variants of the same technique (49,55). Indeed, it has been found that between-variant 
differences can be more important than between-technique differences.   
 
Evidence that the way people are asked about their preferences has a major impact on 
the results raises questions about the nature of people’s preferences for health states.  
It suggests that people do not have well-defined preferences about health before the 
interview; rather, their preferences are constructed during the interview.  This would 
account for the apparent willingness of respondents to be influenced by the precise 
framing of the question.   
 
A common criticism of the current methods for eliciting preference is that the tasks 
are cognitively complex, with respondents being asked to consider variations in up to 
eight health dimensions alongside a life-and-death scenario involving probabilities of 
survival.  Evidence from psychology suggests that respondents faced with such 
complex problems would tend to adopt simple heuristic strategies (56). This would be 
particularly true where respondents have little time to consider their real underlying 
values.  
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The foregoing underscores the need to develop respondent-friendly methods. A well-
conducted study involving the elicitation of preferences should fully explain the task 
to the respondent and undertake a practice question.  Unfortunately, respondents are 
typically expected to evaluate health states in one sitting, with little time for 
reflection.  Respondents need more time and support to reflect on their values in order 
to process such complex information. It has been suggested that respondents could be 
re-interviewed after they have had time to deliberate on the health state in question.  
Shiell and colleagues (57) found significant differences between interviews for the 
same states, with values tending to be higher at subsequent sittings. An implication 
may be to move away from the current large-scale  surveys of members of the general 
public involving a single sitting to smaller-scale studies of panels from the general 
public who are better trained and more experienced in the techniques and who are 
given time to fully reflect on their valuations.  
 
States worse than dead 
For states deemed worse than dead, the SG technique asks the respondent to choose 
between the prospect of death for certain and the uncertain prospect of full health or 
the state being valued.  The probability of full health is varied until the point of 
indifference where the value of the state worse than death is –P/ (1-P).  The analogous 
TTO question asks respondents to choose between the first alternative of dying 
immediately and the second alternative of some number of years in the state being 
valued followed by a number of years in full health (where the two periods sum to t).  
The time in full health x is varied until the person is indifferent between these 
alternatives.  The value for the state worse than death is then given by –x/(x-t).  These 
two formulas, together with the method for calculating the value of states better than 
dead, produce a range of values between +1 and -¥, which gives greater weight to 
negative values in the calculation of mean health state scores and presents problems in 
statistical analysis.  To reduce the influence of extreme negative outliers, Patrick and 
colleagues (58) proposed transforming the values to limit the range from +1 to –1.  
 
It is important to consider states worse than being dead because they are common 
among preference-based measures. The UK TTO valuation of the EQ-5D, for 
example, produced mean scores below zero for one-third of all states.  Evidence from 
the UK valuation of the EQ-5D suggests a discontinuity around zero that appears to 
indicate a special significance is attached to this value.  Once people regard a health 
state as worse than death, they are willing to give quite a low value.  Doubts must 
exist about whether the scale has the same interval properties either side of zero.  
More research is needed into the valuation of states worse than death.    
 
Source of values 
There is evidence of significant variation in values by disease experience, age, and 
education.  In general the evidence points to patients giving health states a higher 
value than do members of the general population (59-61).   
 
The Washington Panel argued that using the values of the general population favors  
patients because general population values give a larger value to treatments that 
restore patients to full health.  Lenert and colleagues, however, have demonstrated 
that values of the general population may be less sensitive to movements between 
points at the lower end of health because of a reference point effect (62).   
Furthermore, the lower health state valuations of the general population work against 
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the interests of patients for life-saving interventions since these lower values result in 
a smaller gain in QALY.  
 
The main normative argument for using general population values seems to hinge on 
the view that in a publicly funded health care system it is society’s resources that are 
being allocated, and therefore it is the views of the general population that are 
relevant. In a similar way, it can be argued that it is enrollees of insurance schemes 
who should be asked to provide values in the context of decisions within a private 
insurance program rather than patients.   By contrast, it has been suggested that the 
values of patients should be used because they are in the best position to know their 
own state (63).   
 
The choice of viewpoint is ultimately a value judgement, but it may depend on the 
reasons for the discrepancy.  The main cause of the difference between the values of 
patients and the general population is adaptation to the condition.  Patients 
experiencing long-term conditions might also change their life goals and expectations.  
These are aspects of the ‘response shift’ recognized in the QOL research literature 
mentioned earlier in this paper. These adaptations will be related to the length of time 
a patient experiences the condition.  
 
Members of the general population know little about such adaptation. The choice 
between patient and general population values really comes down to the extent to 
which these changes should be taken into account.  Menzel et al (64) tried to 
distinguish between ‘laudable’ adaptations, such as enhancing one’s skills, adjusting 
activities, and even altering perceptions of health, and less desirable changes such as 
cognitive denial of functional health and suppressed recognition of full health.  There 
is also a genuine concern that many of the changes listed are the result of laudable 
effort, and incorporating them into health state values in resource allocation may work 
against patients’ interests, which seems in some sense unfair.   
 
It seems difficult to justify using just patient values or uninformed members of the 
general population to obtain preferences for health measures. Menzel and colleagues 
(64) suggest that more research is required into the causes of adaptation.  They also 
suggest that patients should be consulted on the extent to which they want their 
adapted values to be used in decision making. This empirical research would not 
address the normative question of what aspects of adaptation should ultimately be 
used.  Menzel et al. suggest rather ambitiously that perhaps the general population 
may be able to disentangle appropriate from inappropriate adaptation.  This is 
consistent with the recommendations of the Washington Panel, which advocate the  
use of informed general population values.  A middle way could be to provide 
members of the general population with patients’ values before asking them for their 
own values. There is important empirical work to be done to develop methods for 
conveying such information to the general population and to measure its impact on 
health state values.  
  
The question of whether values from one country or culture can be used in another is 
also an important one.   The emerging evidence suggests that VAS valuations do not 
vary much between countries, but there are significant differences between countries 
in TTO values for EQ-5D (9,16,65) and SG valuations of the SF-6D (27) and HUI-2 
(52). It seems there are significant differences between countries in health state values 
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and important variations by sociodemographic characteristics and ethnic group 
(16,66).   
 
Method of extrapolation 
There have been two approaches to estimating a function for valuing states from a 
health state classification system, the decomposed and composite approaches (33). 
 
The decomposed approach employs MAUT to determine the functional form and the 
sample of states to be valued.  MAUT substantially reduces the valuation task by 
making simplifying assumptions about the relationship between dimensions.  The 
most commonly used specifications are the additive and multiplicative functional 
forms.  The simple additive functional form assumes dimensions to be independent 
and hence permits no interaction. This was found by Torrance et al. (13) to be invalid, 
and the multiplicative function has been used to value the HUI-2 and HUI-3. The 
multiplicative function permits a very limited form of interaction between dimensions 
by assuming the interdependency is the same between all dimensions and for all 
levels of each dimension.  
 
The application of MAUT decomposes the valuation task into three parts.  First, each  
dimension is valued separately to estimate single-attribute utility functions.  Second,  
‘corner states’ are valued; these are states where one dimension is at one extreme 
(usually the worst level) and the rest are set at the other (usually the best) level.  Such 
‘corner states’ may represent infeasible combinations of dimension levels unless the 
descriptive system ensures the dimensions are truly independent. A failure to achieve 
this with the HUI-2 resulted in a complex ‘backing-off’ procedure (13). Third, a set of 
multi-attribute states determined by the model specification is valued.  A single 
respondent undertakes all tasks for the HUI-2 and 3.  
 
The composite approach requires a rather larger sample of states to estimate a 
function by regression.  A common method for sampling states is to use an orthogonal 
design for estimating an additive model.  There are problems, however, with 
determining the states required to estimate a model with interaction terms.  To date, 
researchers have typically added extra states at random.  An important piece of 
research will be to develop more sophisticated algorithms for sampling health states in 
order to value key interactions. The statistical models developed for the EQ-5D and 
SF-6D have estimated crude summary terms for interactions, such as dummy 
variables taking a value of one for states containing at least one dimension at its worst 
level (15,17).   
 
The composite approach requires more states than can be valued by a single 
respondent.  The sample states are allocated between respondents, and thus it is 
necessary to disentangle variation between respondents from variation between states.  
The statistical modelling has to cope with this hierarchical structure to the data set,  
and researchers have done this using random effects techniques or by modelling mean 
health state values (15,17). Modelling also has to cope with a highly skewed data set.  
Work in this area has explored a range of transformations to overcome this problem, 
but none has been found to improve the models.  Recently, work has been undertaken 
to use a Bayesian approach that applies a nonparametric method to estimating 
posterior mean health state values with variances, and the first application to the SF-
6D has proved very successful (67).   
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There has been little written comparing statistical and MAUT approaches. The 
MAUT multiplicative models are (in a limited sense) more sophisticated than the 
additive EQ-5D, but they are based on the valuation of a far smaller number of health 
states. The MAUT approach uses deterministic models and does not allow for the 
pattern of the error structure.  For HUI-2 and HUI-3, VAS was used to value the 
health states, which means the transformation may introduce another source of error.  
In principle, however, it is possible to apply the MAUT approach using SG (or TTO) 
directly. 
 
The choice between these approaches must rest on their ability to predict health state 
values in an independent sample.  A comparison of the MAUT and statistical 
approaches was undertaken two decades ago in a study of job choice by Currim and 
Sarin (68). The authors found the statistical approach outperformed a multiplicative 
algebraic model: the correlation between actual and predicted choices across jobs 
using SG utility values was 0.64 and 0.16, respectively.   This was a very limited 
study, however, and not in the context of health.   A recent study by McCabe (69) 
applied the MAUT and statistical approaches to the UK valuation of the HUI-3 and 
found that the statistical approach was marginally better in terms of absolute mean 
error and percent within the range of plus or minus 0.1 and 0.05 of actual values.   
This evidence is also not conclusive because it is also influenced by the VAS-SG 
mapping.     
 
The ensuing debate between MAUT and the statistical approach requires a head-to-
head comparison where the two are used optimally, with the statistical approach being 
based on a better sampling procedure and the MAUT using SG or TTO in a direct 
fashion.  
 
FUTURE AVENUES  FOR RESEARCH    
 
Descriptive systems of existing PBMH    
The psychometric properties of existing PBMH need to be better understood through 
head-to-head comparisons with each other and with non-preference-based measures 
of health.  These data would permit the application of IRT and classical psychometric 
assessments of the validity of the descriptive systems of these instruments.  
 
Comparison of existing measures 
There is currently research under way to compare the PBMH in different patient 
groups.  This will provide a better understanding of the relationship between existing 
measures and should contribute to an understanding of the reasons for the differences 
between these measures.  
  
Source of values 
There are two related pieces of research into this component. The first will be to elicit 
patient health values alongside PBMH across a wide range of patient groups.   This 
will help us understand the differences between patient and general population values 
and how the differences vary between medical condition and other background 
variables.  The second would be to examine the use of informed general population 
values.  This would require research into using patient values in valuing health states 
among the general population.     
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Methods for eliciting preferences  
There is increasing interest in using ordinal tasks, like ranking or pairwise 
comparison, to derive the values of health states, and these could prove particularly 
valuable in enfranchising the more vulnerable groups.  Second, the potential role of 
reflection and deliberation in the valuation of health states needs to be explored in 
future valuation surveys of PBMH.    
 
States worse than being dead 
Research is needed into developing ways to value states worse than being dead that lie 
on the same scale as states better than being dead.  
 
Estimation 
Further research is needed into estimating preference-based index measures from a 
sample of health state valuations.  MAUT should be applied directly using SG and 
TTO, and statistical modelling can be improved including the use of Bayesian 
approaches; then, the different approaches need to be compared.   
 
Compare existing measures or develop a new one? 
For any major program of research an important question is whether to use existing 
measures.  In the short to medium term the use of existing measures, such as the 
recently completed valuation of the EQ-5D and SF-36, makes good use of existing 
data sets.  In the longer term, however, there could be a case for developing new 
measures drawing on more recent psychometric literature (including IRT) and 
valuation (such as the use of ordinal methods).  This research is particularly important 
in the more vulnerable groups such as children, the very elderly, and people with 
major mental health problems, where existing measures are often inappropriate.   
 
CONCLUSION 
PBHM have come a long way over the last 20 years and offer an important set of 
tools for economic evaluation and other uses of summary health measures.  Existing 
instruments differ in their descriptive systems and methods of valuation, and so they 
often generate different scores.  Recent developments in assessing and valuing  health 
status provide an important basis for improving preference-based health measurement 
and for developing more appropriate instruments for special groups, including 
vulnerable groups such as the very young, the very elderly, and people with serious 
mental health problems.  The challenge is to ensure that new instruments provide a 
means of generating standardized and comparable scores across populations.   
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Table 1: Characteristics of multi-attribute utility scales 
 
MAUS Descriptive characteristics 
 
Valuation characteristics 
 Dimension  Levels  Health 
states 
Valuation 
technique 
Method of 
extrapolation 
Sample Country 
        
QWB Mobility, physical activity,  
social functioning 
27 symptoms/problems 
 
3 
2 
 
1170 VAS  Statistical 866 (General 
population) 
USA (San 
Diego) 
HUI-2 
 
 
 
HUI-3 
Sensory,  mobility, emotion, cognitive, self-care, pain, 
fertility    
 
Vision, hearing, speech, ambulation, dexterity, emotion, 
cognition, pain 
 
4-5 
3 
 
5-6 
 
 
24,000 
 
 
 
972,000 
 
 
VAS tranformed 
into SG 
 
 
 
MAUT 
 
 
MAUT 
 
203 (parents) 
 
 
 
504 (General 
population) 
Canada 
(Hamilton), 
UK 
 
 
Canada 
(Hamilton), 
France 
 
EQ-5D Mobility, self-care, usual activities, pain/discomfort, 
anxiety/depression   
 
3 
 
243 TTO and VAS  
 
Statistical 
 
 
3395 (General 
population) 
 
UK, Japan, 
Spain, USA 
(among 
others) 
 
 
SF-6D Physical functioning, role limitation, social functioning, 
pain, energy, mental health  
4-6 18,000 SG Statistical 611 (General 
population) 
UK, Japan, 
Hong Kong 
 
Note: VAS – visual analogue scale, TTO – Time trade-off, SG – standard gamble, MAUT – multi-attribute utility theory 
